These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34396638)

  • 1. Successful Treatment of Afatinib Reversing Epidermal Growth Factor Receptor Exon19Deletion/G724S Mutation Resistance Guided by Protein-Drug Docking.
    Yu N; Xu Y; Wang X; Sun C; Qiu S; Guo Y; Bai M; Huang Y; Ma K
    Oncologist; 2021 Nov; 26(11):e1903-e1908. PubMed ID: 34396638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies.
    Cortiula F; Pelizzari G; Corvaja C; De Maglio G; Fasola G
    Anticancer Drugs; 2022 Oct; 33(9):960-962. PubMed ID: 35979997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NSCLC patients with rare
    Wang H; Yu Q; Shi L; Hou Q; Dan L; Liang C; Hong X; Zhao Y; Ning R
    Front Oncol; 2022; 12():1054593. PubMed ID: 36505860
    [No Abstract]   [Full Text] [Related]  

  • 4. Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case report.
    Jiang Y; Zhang J; Jiang X; Cheng L; Liao X; Li Y; Zhang M; Chen R; Yin T
    Ann Palliat Med; 2021 Jun; 10(6):7051-7056. PubMed ID: 33548986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation.
    Brown BP; Zhang YK; Westover D; Yan Y; Qiao H; Huang V; Du Z; Smith JA; Ross JS; Miller VA; Ali S; Bazhenova L; Schrock AB; Meiler J; Lovly CM
    Clin Cancer Res; 2019 Jun; 25(11):3341-3351. PubMed ID: 30796031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Afatinib as a Potential Therapeutic Option for Patients With NSCLC With
    Wei Y; Jiang B; Liu S; Zhang Z; Fang W; Yang Y; Li X; Zhao J; Zhao H
    JTO Clin Res Rep; 2021 Jul; 2(7):100193. PubMed ID: 34590038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review.
    Zhang C; Lin L; Zuo R; Wang Y; Chen P
    Thorac Cancer; 2020 Sep; 11(9):2743-2748. PubMed ID: 32776462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of Patients with
    Sanchis-Borja M; Guisier F; Swalduz A; Curcio H; Basse V; Maritaz C; Chouaid C; Auliac JB
    Onco Targets Ther; 2024; 17():439-448. PubMed ID: 38836187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term response in a patient with adenocarcinoma harboring both common and uncommon EGFR mutations.
    Okauchi S; Satoh H
    Invest New Drugs; 2022 Dec; 40(6):1354-1355. PubMed ID: 36152106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
    Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
    Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report.
    Kunimasa K; Sugimoto N; Tamiya M; Inoue T; Kawamura T; Kanzaki R; Okami J; Nishino K
    Invest New Drugs; 2022 Oct; 40(5):1137-1140. PubMed ID: 35657573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming EGFR
    Fassunke J; Müller F; Keul M; Michels S; Dammert MA; Schmitt A; Plenker D; Lategahn J; Heydt C; Brägelmann J; Tumbrink HL; Alber Y; Klein S; Heimsoeth A; Dahmen I; Fischer RN; Scheffler M; Ihle MA; Priesner V; Scheel AH; Wagener S; Kron A; Frank K; Garbert K; Persigehl T; Püsken M; Haneder S; Schaaf B; Rodermann E; Engel-Riedel W; Felip E; Smit EF; Merkelbach-Bruse S; Reinhardt HC; Kast SM; Wolf J; Rauh D; Büttner R; Sos ML
    Nat Commun; 2018 Nov; 9(1):4655. PubMed ID: 30405134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib.
    Yamaoka T; Ohba M; Matsunaga Y; Tsurutani J; Ohmori T
    J Vis Exp; 2019 Jun; (148):. PubMed ID: 31305510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
    BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations.
    Liang SK; Ko JC; Yang JC; Shih JY
    Lung Cancer; 2019 Jul; 133():103-109. PubMed ID: 31200815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
    Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
    Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report.
    He SY; Lin QF; Chen J; Yu GP; Zhang JL; Shen D
    World J Clin Cases; 2021 Feb; 9(6):1329-1335. PubMed ID: 33644199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.